Black Hawk Acquisition Corp 8-K

What Happened
Black Hawk Acquisition Corp (BKHA) reported that its proposed business-combination target, Vesicor Therapeutics, Inc., appointed Dr. Michael Tolentino as Chief Executive Officer effective March 17, 2026. Vesicor and Dr. Tolentino executed an Employment Agreement dated March 17, 2026. On the same date, former Vesicor CEO Luo Feng transitioned to Chief Scientific Officer.

Key Details

• Employment term: initial 3‑year term from March 17, 2026, with automatic one‑year renewals unless 90 days’ prior notice is given.
• Base salary: $48,000 (subject to revision if Vesicor raises at least $5 million).
• Severance: if terminated for Good Reason or without cause and the CEO signs an effective general release, Vesicor will pay severance equal to two times then‑current base salary and target annual bonus and, subject to conditions, up to 24 months of group health premium coverage.
• Other material terms: discretionary annual bonus, 60‑day cure period for Good Reason terminations, confidentiality and invention-assignment provisions, non-compete during employment and for one year after, governed by Florida law.

Why It Matters
This filing informs investors that Vesicor — the company BKHA is targeting for a merger — has installed a new CEO with extensive biopharma experience, which could affect Vesicor’s operational leadership and clinical development strategy. The Employment Agreement outlines modest base pay but meaningful severance protections and restrictive covenants (non-compete, confidentiality), details that matter for governance, cash needs, and future leadership costs. Investors watching BKHA’s SPAC deal should note the management change at Vesicor and the contractual commitments disclosed in the 8‑K.